GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (OTCPK:ASCLF) » Definitions » Debt-to-Revenue

ASCLF (Ascletis Pharma) Debt-to-Revenue : 2.98 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascletis Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Ascletis Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.86 Mil. Ascletis Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.19 Mil. Ascletis Pharma's annualized Revenue for the quarter that ended in Dec. 2024 was $0.35 Mil. Ascletis Pharma's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 2.98.


Ascletis Pharma Debt-to-Revenue Historical Data

The historical data trend for Ascletis Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Debt-to-Revenue Chart

Ascletis Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only 0.05 0.04 0.08 0.15 5.96

Ascletis Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.03 0.42 N/A 2.98

Competitive Comparison of Ascletis Pharma's Debt-to-Revenue

For the Biotechnology subindustry, Ascletis Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascletis Pharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's Debt-to-Revenue falls into.


;
;

Ascletis Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Ascletis Pharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.858 + 0.191) / 0.176
=5.96

Ascletis Pharma's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.858 + 0.191) / 0.352
=2.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.


Ascletis Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascletis Pharma Business Description

Traded in Other Exchanges
Address
198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.

Ascletis Pharma Headlines